Active substance
Results for the substance emtricitabine+rilpivirine+tenofovir alafenamide
1 result
About this active substance
The combination of emtricitabine, rilpivirine, and tenofovir alafenamide is used for the treatment of HIV-1 infection in patients with an undetectable viral load. It combines a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and a nucleotide analog to inhibit viral replication.
The medication is taken orally, once daily with food, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, headaches, fatigue, or insomnia. In rare cases, severe allergic reactions, lactic acidosis, or renal impairment may occur.
This combination is not recommended for patients with severe renal impairment or hypersensitivity to any of the components.
The medication is taken orally, once daily with food, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, headaches, fatigue, or insomnia. In rare cases, severe allergic reactions, lactic acidosis, or renal impairment may occur.
This combination is not recommended for patients with severe renal impairment or hypersensitivity to any of the components.